Lemur tail kinase 3 serves as a predictor of patient outcomes and a target for the treatment of ovarian cancer
Authors:
Open Access
- 26 August 2024
- journal article
- research article
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 32 (3) , 200864
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Binding of Intracellular Myeloperoxidase to αV/β1 Integrin Serves as a Mechanism of Survival in Epithelial Ovarian CancerReproductive Sciences, 2022
- The LMTK-family of kinases: Emerging important players in cell physiology and pathogenesisBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2021
- LMTK3 promotes tumorigenesis in bladder cancer via the ERK/MAPK pathwayFEBS Open Bio, 2020
- Identification of curcumin derivatives as human LMTK3 inhibitors for breast cancer: a docking, dynamics, and MM/PBSA approach3 Biotech, 2018
- Advances in ovarian cancer therapyCancer Chemotherapy and Pharmacology, 2017
- Development of immunoaffinity chromatographic method for Ara h 2 isolationProtein Expression and Purification, 2017
- Specific point mutations in key redox enzymes are associated with chemoresistance in epithelial ovarian cancerFree Radical Biology and Medicine, 2017
- LMTK3 Represses Tumor Suppressor-like Genes through Chromatin Remodeling in Breast CancerCell Reports, 2015
- Serum lemur tyrosine kinase 3 expression in colorectal cancer patients predicts cancer progression and prognosisMedical Oncology, 2013
- LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcomeBreast Cancer Research and Treatment, 2011